Pulse corticosteroid therapy for alopecia areata in children: a retrospective study

Rivka Friedland1, Rotem Tal, Moshe Lapidoth

  • 1Department of Dermatology, Rabin Medical Center, Petach Tikva, Israel.

Dermatology (Basel, Switzerland)
|September 7, 2013
PubMed

Insights

Intravenous high-dose pulse corticosteroids show moderate effectiveness for pediatric alopecia areata, with relapse common. Shorter disease duration, younger age, and multifocal disease predict better outcomes.

Area of Science:

  • Pediatric Dermatology
  • Autoimmune Disorders
  • Clinical Therapeutics

Background:

  • Alopecia areata commonly affects children and adolescents.
  • Systemic steroids, particularly high-dose pulse infusions, are a frequent treatment modality.
  • Identifying predictors of treatment success is crucial for optimizing patient care.

Purpose of the Study:

  • To evaluate the efficacy and safety of intravenous high-dose pulse corticosteroids in pediatric alopecia areata.
  • To determine prognostic factors associated with successful treatment outcomes.
  • To assess the long-term relapse rates following treatment.

Main Methods:

  • A retrospective analysis of 24 children with alopecia areata treated between 2001-2008.
  • Patients received intravenous methylprednisolone (8 mg/kg) over 3 consecutive days monthly.
  • Data on treatment response, side effects, and prognostic factors were collected.

Main Results:

  • 38% achieved complete response, 29% partial response, and 33% no response after a mean of 5.65 courses.
  • 81% of responders relapsed within 9.5 months.
  • Positive prognostic factors included short disease duration (≤6 months), younger age at onset (<10 years), and multifocal disease.

Conclusions:

  • Pulse corticosteroid therapy offers a viable treatment option for pediatric alopecia areata, though relapse is frequent.
  • Careful patient selection based on prognostic factors can maximize treatment benefits.
  • Further research into long-term management strategies is warranted.
Abstract

Related Concept Videos

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...
Cushing Syndrome I: Introduction01:26

Cushing Syndrome I: Introduction

Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the syndrome.Exogenous...